Quantamental Technologies LLC acquired a new position in shares of Lantheus Holdings Inc (NASDAQ:LNTH) during the 2nd quarter, Holdings Channel.com reports. The fund acquired 1,962 shares of the medical equipment provider’s stock, valued at approximately $56,000.
A number of other institutional investors have also modified their holdings of LNTH. JPMorgan Chase & Co. grew its position in Lantheus by 41.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,034,497 shares of the medical equipment provider’s stock worth $28,584,000 after purchasing an additional 304,537 shares during the last quarter. Prudential Financial Inc. boosted its holdings in shares of Lantheus by 52.7% in the second quarter. Prudential Financial Inc. now owns 645,884 shares of the medical equipment provider’s stock valued at $18,278,000 after acquiring an additional 223,029 shares in the last quarter. Landscape Capital Management L.L.C. purchased a new stake in shares of Lantheus in the second quarter valued at about $4,138,000. Charles Schwab Investment Management Inc. boosted its holdings in shares of Lantheus by 60.0% in the second quarter. Charles Schwab Investment Management Inc. now owns 342,632 shares of the medical equipment provider’s stock valued at $9,697,000 after acquiring an additional 128,503 shares in the last quarter. Finally, CIBC World Markets Inc. purchased a new stake in shares of Lantheus in the first quarter valued at about $2,471,000. 95.73% of the stock is currently owned by institutional investors.
Shares of NASDAQ LNTH traded up $0.38 during midday trading on Friday, hitting $24.41. The company had a trading volume of 4,531 shares, compared to its average volume of 275,368. The company has a quick ratio of 2.01, a current ratio of 2.62 and a debt-to-equity ratio of 2.05. Lantheus Holdings Inc has a twelve month low of $12.59 and a twelve month high of $29.80. The business has a 50-day simple moving average of $22.62 and a two-hundred day simple moving average of $24.74. The firm has a market capitalization of $869.96 million, a price-to-earnings ratio of 25.71, a price-to-earnings-growth ratio of 1.87 and a beta of 1.50.
Lantheus (NASDAQ:LNTH) last announced its quarterly earnings data on Thursday, July 25th. The medical equipment provider reported $0.27 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.27. The firm had revenue of $85.70 million during the quarter, compared to analysts’ expectations of $88.72 million. Lantheus had a net margin of 11.20% and a return on equity of 51.08%. The business’s revenue for the quarter was up .1% compared to the same quarter last year. During the same quarter last year, the business earned $0.25 earnings per share. On average, equities analysts forecast that Lantheus Holdings Inc will post 1 EPS for the current year.
Several analysts have recently weighed in on LNTH shares. Zacks Investment Research downgraded shares of Lantheus from a “hold” rating to a “sell” rating in a report on Friday, August 2nd. BidaskClub raised shares of Lantheus from a “hold” rating to a “buy” rating in a report on Friday. ValuEngine downgraded shares of Lantheus from a “buy” rating to a “hold” rating in a report on Thursday, August 1st. Finally, CJS Securities upgraded shares of Lantheus from a “market perform” rating to an “outperform” rating in a research note on Friday, August 16th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and two have given a buy rating to the stock. Lantheus has a consensus rating of “Hold” and an average target price of $29.00.
In other Lantheus news, CEO Mary Anne Heino sold 25,538 shares of Lantheus stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $21.21, for a total transaction of $541,660.98. Following the completion of the transaction, the chief executive officer now owns 597,884 shares in the company, valued at $12,681,119.64. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Michael P. Duffy sold 5,604 shares of Lantheus stock in a transaction dated Wednesday, September 4th. The stock was sold at an average price of $20.60, for a total transaction of $115,442.40. Following the transaction, the senior vice president now owns 138,890 shares of the company’s stock, valued at approximately $2,861,134. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 111,552 shares of company stock valued at $2,911,266. 2.60% of the stock is currently owned by company insiders.
Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, a microbubble contrast agent used in ultrasound exams of the heart; and TechneLite, a technetium generator that provides the nuclear material used in nuclear medicine procedures.
Featured Story: Stock Portfolio Tracker
Want to see what other hedge funds are holding LNTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lantheus Holdings Inc (NASDAQ:LNTH).
Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.